Century Therapeutics, Inc. (IPSC): Cash & Equivalents
$61.85M
As of 2025-12-31
$49.64M
As of 2026-06-30
-9.8%
3-year compound annual growth
+17.8%
5-year compound annual growth
| Period ended | Cash & Equivalents | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $61.85M | +5.8% | 2026-03-12, Balance as of period end |
| 2024-12-31 | $58.44M | +23.5% | 2026-03-12, Balance as of period end |
| 2023-12-31 | $47.32M | -43.8% | 2025-03-19, Balance as of period end |
| 2022-12-31 | $84.27M | +49.3% | 2024-03-14, Balance as of period end |
| 2021-12-31 | $56.45M | +107.4% | 2023-03-16, Balance as of period end |
| 2020-12-31 | $27.21M | n/a | 2022-03-17, Balance as of period end |
Cash & Equivalents at similar companies
| Company | Year ended | Cash & Equivalents | Change YoY |
|---|---|---|---|
| Century Therapeutics, Inc. (IPSC) | 2025-12-31 | $61.85M | +5.8% |
| ImmunityBio, Inc. (IBRX) | 2025-12-31 | $88.33M | -38.4% |
| Agenus Inc (AGEN) | 2025-12-31 | $3.00M | -92.6% |
| Sutro Biopharma, Inc. (STRO) | 2025-12-31 | $58.13M | -69.5% |
| Atara Biotherapeutics, Inc. (ATRA) | 2025-12-31 | $8.48M | -66.1% |
| Monte Rosa Therapeutics, Inc. (GLUE) | 2025-12-31 | $129.88M | -42.1% |
| Beam Therapeutics Inc. (BEAM) | 2025-12-31 | $294.94M | +4.6% |
| 4D Molecular Therapeutics, Inc. (FDMT) | 2025-12-31 | $60.24M | -59.7% |
| MeiraGTx Holdings plc (MGTX) | 2025-12-31 | $65.93M | -36.4% |
Compare IPSC, IBRX, AGEN, STRO side by side · Screen every company in Biological Products, (No Diagnostic Substances) ↗